Gerard J. Michel
Gerard J. Michel's purchase track record
How the stock did after each of Gerard J. Michel's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/2/2026 | DCTH | $100K | +18.7% | +84.3% | +11.7% |
| 11/11/2025 | DCTH | $98K | +17.2% | +31.6% | +8.1% |
| 12/8/2023 | DCTH | $100K | +33.7% | +119.8% | +16.1% |
| 3/29/2023 | DCTH | $95K | +5.6% | -27.4% | +6.1% |
| 12/13/2022 | DCTH | $150K | +26.2% | +86.8% | +8.7% |
| 7/20/2022 | DCTH | $250K | -26.0% | -5.5% | -0.8% |
| 4/18/2022 | DCTH | $13K | -37.1% | -53.8% | -16.3% |
| 4/8/2022 | DCTH | $13K | -37.2% | -53.6% | -18.9% |
| 12/2/2021 | DCTH | $200K | -32.2% | -51.3% | -8.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Veracyte stock moves; DCTH shows no related news. Recent news coverage focuses on Veracyte (VCYT) rather than Delcath Systems (DCTH). There are no specific reports or announcements regarding DCTH in the provided data. The stock currently trades with a high trailing P/E ratio, while analyst targets remain above the current price level.
Transaction History
| BBNX | ▲ Buy | Grant | 16,965 | $0 | 5/21/2026 | View on chart |
| DCTH | ▲ Buy | Open Market | 11,200 | $100K | 3/2/2026 | View on chart |
| BBNX | ▲ Buy | Grant | 3,997 | $0 | 1/13/2026 | View on chart |
| DCTH | ▲ Buy | Open Market | 11,500 | $98K | 11/11/2025 | View on chart |
| BBNX | ▲ Buy | Grant | 12,547 | $0 | 3/26/2025 | View on chart |
| DCTH | ▲ Buy | Option Exercise | 16,666 | $100K | 10/22/2024 | View on chart |
| DCTH | ▲ Buy | Grant | 40,323 | $150K | 3/19/2024 | View on chart |
| DCTH | ▲ Buy | Open Market | 34,000 | $100K | 12/8/2023 | View on chart |
| DCTH | ▼ Sell | Other | 31,110 | $140K | 8/18/2023 | View on chart |
| DCTH | ▲ Buy | Open Market | 19,646 | $95K | 3/29/2023 | View on chart |
| DCTH | ▲ Buy | Open Market | 51,725 | $150K | 12/13/2022 | View on chart |
| DCTH | ▲ Buy | Open Market | 62,814 | $250K | 7/20/2022 | View on chart |
| DCTH | ▲ Buy | Open Market | 200 | $1K | 4/18/2022 | View on chart |
| DCTH | ▲ Buy | Open Market | 1,800 | $11K | 4/18/2022 | View on chart |
| DCTH | ▲ Buy | Open Market | 1,000 | $7K | 4/8/2022 | View on chart |
| DCTH | ▲ Buy | Open Market | 1,000 | $7K | 4/8/2022 | View on chart |
| DCTH | ▲ Buy | Open Market | 23,200 | $200K | 12/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Beta Bionics Signs Senseonics Deal, Gets New Analyst Coverage
Beta Bionics announced an agreement to integrate its iLet Bionic Pancreas with Senseonics' Eversense 365 sensor. This partnership aims to create a more comprehensive automated insulin delivery system. Additionally, Wells Fargo initiated coverage with an Overweight rating and a $28 price target, while Truist raised its target to the same level. The stock is currently trading within its 52-week range, with an average analyst target of $22.40.
Beta Bionics Signs Senseonics Deal, Gets New Analyst Coverage. Beta Bionics announced an agreement to integrate its iLet Bionic Pancreas with Senseonics' Eversense 365 sensor. This partnership aims to create a more comprehensive automated insulin delivery system. Additionally, Wells Fargo initiated coverage with an Overweight rating and a $28 price target, while Truist raised its target to the same level. The stock is currently trading within its 52-week range, with an average analyst target of $22.40.